Minze Health Secures $5.3 Million in Funding to Advance Digital Health Solutions for Urology
Minze Health, a leader in digital health solutions tailored for urology, has successfully raised $5.3 million in a funding round spearheaded by its current investors—White Fund, Capricorn Digital Growth Fund, and the Flemish investment company PMV. Notably, this funding round also welcomed a new participant, the imec.istart future fund, signifying a pivotal advancement for the company’s growth and innovation trajectory.
The capital raised will be directed toward the development and market introduction of Prescription Digital Therapeutics (PDTs) aimed at addressing urinary dysfunctions, with a primary focus on Germany and France. Additionally, Minze Health plans to facilitate entry into the U.S. market with its innovative at-home diagnostic solutions.
Minze Health’s suite of solutions has already benefitted over 160,000 patients across more than 20 countries, showcasing its reputation among clinicians worldwide. By offering a diverse range of Digital Diagnostics, Remote Patient Monitoring, and Digital Therapeutics products, Minze Health stands out as a key player in the urology sector.
Enhancing Care with Homeflow and Diary Pod Products
The funding will specifically enhance the utilization of Minze Health’s Homeflow and Diary Pod products in the U.S. market. Homeflow is an at-home uroflowmetry system that can be billed under the newly established Category III CPT codes, providing a significant opportunity to serve patients with benign prostatic hyperplasia (BPH) and similar conditions. This solution offers critical advantages for managing BPH, which impacts over 14 million men in the United States.
By enabling patients to monitor urinary flow from home, Homeflow equips clinicians with continuous data, facilitating the development of personalized treatment plans. This non-invasive approach minimizes the need for frequent clinic visits and empowers patients to take charge of their symptoms, allowing for earlier detection and timely interventions.
Strategic Appointment and Market Expansion
In alignment with its ambitious U.S. expansion plans, Minze Health is excited to announce the appointment of Drew Moore as Vice President of Marketing & Sales. With over 20 years of experience in launching innovative digital healthcare and medical device products—especially in urology—Drew’s expertise will be vital in establishing Minze Health’s U.S. office and building a robust team to support the company’s growth and market presence.
Additionally, the funds will aid in launching Prescription Digital Therapeutics (PDTs) for patients experiencing lower urinary tract symptoms (LUTS), initially targeting Germany and France. The company plans to leverage the DIGA and PECAN reimbursement schemes to facilitate this initiative. The PDT market is rapidly evolving, driven by technological advancements and a growing demand for personalized, non-invasive treatment options.
Digital therapies, validated through clinical studies and accessible via mobile apps, are gaining traction across various medical fields. Urological conditions like LUTS and overactive bladder (OAB) are particularly well-suited for PDTs, as these therapies not only address physiological symptoms but also incorporate cognitive interventions to influence lifestyle and behavior. By empowering patients to manage their conditions remotely, PDTs have the potential to revolutionize the treatment landscape for urological disorders, enhancing patient outcomes while lowering healthcare costs.
Investor Insights
Philippe Stas, Executive Committee Member at White Fund, expressed pride in supporting Minze’s international expansion. “Their innovative solutions, such as Homeflow, fill crucial gaps in patient care and can substantially improve outcomes for millions globally,” he stated.
Ruth Janssens, Managing Partner at imec.istart future fund, added, “Minze Health has shown remarkable progress in digital health. We’re thrilled to support their journey into the U.S. market with pioneering products like Homeflow, aligning with our vision of investing in companies that drive impactful change through technology.”
Wilfried Woesthuis, CEO at Minze Health, expressed gratitude for the continued support from existing investors and the new partnership with imec.istart future fund. He emphasized, “This funding positions us to expand internationally and bring innovative solutions to the urology market. Our goal is to enhance the quality of life for those with conditions like BPH and OAB.”
About Minze Health
Minze Health specializes in developing transformative solutions for diagnosing, monitoring, and treating urinary conditions. Its innovative products, including Homeflow, are designed to improve patient outcomes while adhering to strict regulatory standards. Headquartered in Belgium, Minze is committed to making a global impact and is rapidly advancing into international markets, particularly the U.S. All Minze products are CE-marked and FDA-listed, developed under stringent GDPR and HIPAA regulations.
